Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.34 |
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.33 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.33 |
| ▸ | ADH1B | P00325 | 1/20 | 0.31 |
| ▸ | ADH1C | P00326 | 1/20 | 0.31 |
| ▸ | ADH1A | P07327 | 1/20 | 0.31 |
| ▸ | ADH4 | P08319 | 1/20 | 0.31 |
| ▸ | ADH7 | P40394 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL672855 | 0.81 | LMNA (0.39) | LMNASLC1A3SLC1A2SLC1A1CTSL | |
| SCHEMBL673790 | 0.78 | LMNA (0.36) | LMNASLC1A3SLC1A2SLC1A1CTSL | |
| SCHEMBL672569 | 0.73 | SLC1A3 (0.34) | LMNASLC1A3SLC1A2SLC1A1PARP10 | |
| SCHEMBL672200 | 0.67 | SLC1A3 (0.30) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL13998789 | 0.67 | — | — | |
| SCHEMBL1703891 | 0.67 | — | — | |
| SCHEMBL1326091 | 0.67 | — | — | |
| SCHEMBL23039739 | 0.66 | CTSL (0.41) | LMNASLC1A3SLC1A2SLC1A1CTSL | |
| SCHEMBL869115 | 0.66 | CTSL (0.41) | LMNASLC1A3SLC1A2SLC1A1CTSL | |
| SCHEMBL379081 | 0.66 | CTSL (0.41) | LMNASLC1A3SLC1A2SLC1A1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013040501-A1 | COMPOSITIONS AND COMBINATIONS OF ORGANOPHOSPHORUS BIOSCAVENGERS AND HYALURONAN-DEGRADING ENZYMES, AND USES THEREOF | PHARMATHENE, INC. (US) | 2013-03-21 | — | — | WO | disclosed |
| US-20130071394-A1 | Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use | PHARMATHENE, INC. | 2013-03-21 | — | — | US | disclosed |
| US-20060246592-A1 | Identification of low vapor pressure toxic chemicals | ARCADIS G&M, INC. | 2006-11-02 | — | — | US | disclosed |
| US-6722182-B1 | Solid state vapor generator | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2004-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130071394-A1 | Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use | ACHE, BCHE, ENGASE | LMNA 2254/4885SLC1A3 1926/4885SLC1A2 1895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.